Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.
Amaury DasteMathieu LarroquetteNyere GibsonMatthieu LasserreCharlotte DomblidesPublished in: Immunotherapy (2023)
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several solid cancers, including head and neck squamous cell carcinoma (HNSCC). First approved for second-line settings, ICIs are now used for the first-line treatment of HNSCCs, mainly in combination with standard chemotherapy. This review focuses on the results of the main phase III studies evaluating ICIs in recurrent or metastatic HNSCCs. The efficacy and indications according to the PD-L1 status, the main predictive biomarker, are discussed. The results of trials assessing ICI efficacy for locally advanced disease, including the neoadjuvant setting are also discussed. Finally, therapeutic combinations that are potential treatments for HNSCCs, including ICIs and targeted therapies such as anti-EGFR agents, are presented.
Keyphrases
- phase iii
- small cell lung cancer
- current status
- locally advanced
- open label
- clinical trial
- squamous cell carcinoma
- rectal cancer
- epidermal growth factor receptor
- phase ii
- double blind
- lymph node
- tyrosine kinase
- risk assessment
- randomized controlled trial
- climate change
- human health
- smoking cessation
- drug administration
- study protocol
- chemotherapy induced